Display options
Cite
Nowara E, Huszno J, Slomian G, et al. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib. Postepy Dermatol Alergol. 2016;33(1):52-6doi: 10.5114/pdia.2015.48045.
Nowara, E., Huszno, J., Slomian, G., & Nieckula, J. (2016). Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib. Postepy dermatologii i alergologii, 33(1), 52-6. https://doi.org/10.5114/pdia.2015.48045
Nowara, Elzbieta, et al. "Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib." Postepy dermatologii i alergologii vol. 33,1 (2016): 52-6. doi: https://doi.org/10.5114/pdia.2015.48045
Nowara E, Huszno J, Slomian G, Nieckula J. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib. Postepy Dermatol Alergol. 2016 Feb;33(1):52-6. doi: 10.5114/pdia.2015.48045. Epub 2016 Feb 29. PMID: 26985180; PMCID: PMC4793055.
Copy Download .nbib Format: NLM
Share it on

Postepy Dermatol Alergol. 2016 Feb;33(1):52-6. doi: 10.5114/pdia.2015.48045. Epub 2016 Feb 29.

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib.

Postepy dermatologii i alergologii

Elzbieta Nowara, Joanna Huszno, Grzegorz Slomian, Jaroslaw Nieckula

Affiliations

  1. Clinical and Experimental Oncology Department, Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
  2. Oncological Ward, Independent Public Health Care Unit, Voivodeship Specialized Hospital, Rybnik, Poland.

PMID: 26985180 PMCID: PMC4793055 DOI: 10.5114/pdia.2015.48045

Abstract

INTRODUCTION: The use of orally available BRAF kinase inhibitor - vemurafenib is associated with numerous adverse skin reactions.

AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessment of the incidence of skin cancer.

MATERIAL AND METHODS: We carried out a systematic study of patients (pts) treated with vemurafenib. Skin toxicity during vemurafenib therapy was analyzed. Toxicity was determined on the basis of the toxicity scale CTCAE, version 4.0.

RESULTS: The most common cutaneous side effects were hyperkeratotic perifollicular rash (69%) and photosensitivity (15%). Skin rash developed more frequently in the first month of treatment. Squamous cell carcinoma occurred in 38% of patients. Patients with skin cancer development during vemurafenib therapy had non-significantly longer overall survival (OS) than patients without skin cancer, p = 0.4. Skin cancer developed more often in women than in men (60% vs. 25%), p = 0.249. It was detected only in patients with normal weight compared to overweight patients (55% vs. 0), p = 0.09. The median OS was 26 months and median OS from the time of distant metastases diagnosis was 9.8 months. In patients with a low body mass index, shorter OS was observed, p = 0.09.

CONCLUSIONS: The incidence of squamous cell carcinoma was high (38%). This study has many limitations mostly due to a small group of patients. That is why the results should be taken into consideration with caution. The proper symptomatic treatment in cooperation with dermatologists allows to continue the vemurafenib therapy.

Keywords: BRAF inhibitor; cutaneous melanoma; skin toxicity; vemurafenib

References

  1. Am J Health Syst Pharm. 2011 May 1;68(9):768 - PubMed
  2. Ann Dermatol Venereol. 2014 Mar;141(3):215-8 - PubMed
  3. J Clin Oncol. 2000 Nov 15;18(22):3782-93 - PubMed
  4. N Engl J Med. 2012 Feb 23;366(8):707-14 - PubMed
  5. Lancet Oncol. 2014 Apr;15(4):436-44 - PubMed
  6. Arch Dermatol. 2012 May;148(5):628-33 - PubMed
  7. Ann Oncol. 2013 Jun;24(6):1691-7 - PubMed
  8. Lancet Oncol. 2014 Apr;15(4):369-70 - PubMed
  9. Pharmacol Res. 2012 Jan;65(1):9-22 - PubMed
  10. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  11. Lancet Oncol. 2014 Mar;15(3):323-32 - PubMed
  12. Lancet. 2012 Jul 28;380(9839):358-65 - PubMed

Publication Types